IRF4 and plasma cell myeloma: Angelique Bruyer et al. reported a new gene expression-based score to predict MM cell sensitivity to the combination of DNMTi/HDACi, and treatment with DNMTi/HDACi downregulated IRF4 and MYC expression which appeared to induce a mature gene expression profile in myeloma cell lines (34).